Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`PTO Form 1960 (Rev 10/2011)
`
`OMB No. 0651-0050 (Exp 09/20/2020)
`
`Request for Reconsideration after Final Action
`
`Input Field
`
`SERIAL NUMBER
`
`LAW OFFICE ASSIGNED
`
`MARK SECTION
`
`MARK
`
`LITERAL ELEMENT
`
`STANDARD CHARACTERS
`
`USPTO-GENERATED IMAGE
`
`MARK STATEMENT
`
`ARGUMENT(S)
`
`The table below presents the data as entered.
`
`Entered
`
`86606416
`
`LAW OFFICE 120
`
`https://tmng-al.uspto.gov/resting2/api/img/86606416/large
`
`LISOLOG
`
`YES
`
`YES
`
`The mark consists of standard characters, without claim to any particular font style,
`size or color.
`
`Please find attached argument and exhibits. 
`
`EVIDENCE SECTION
`
`        EVIDENCE FILE NAME(S)
`
`       ORIGINAL PDF FILE
`
`       CONVERTED PDF FILE(S)
`       (9 pages)
`
`       ORIGINAL PDF FILE
`
`       CONVERTED PDF FILE(S)
`       (94 pages)
`
`evi_1214420254-20171006133904271407_._LisologReqforRecon.pdf
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0002.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0003.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0004.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0005.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0006.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0007.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0008.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0009.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0010.JPG
`
`evi_1214420254-20171006133904271407_._lisologExhibits.pdf
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0011.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0012.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0013.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0014.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0015.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0016.JPG
`
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`

`

`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0017.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0018.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0019.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0020.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xml6\RFR0021 .JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0022.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0023.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0024.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0025.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0026.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0027.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0028.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0029.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0030.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xml6\RFR003 1 .JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0032.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0033.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0034.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0035.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0036.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0037.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0038.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0039.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0040.JPG
`
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xml6\RFR0041 .JPG
`
`
`
`
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0042.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0043.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0044.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0045.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0046.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0047.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0048.JPG
`
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0049.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0050.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR005 1 .JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0052.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0053.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0017.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0018.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0019.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0020.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0021.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0022.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0023.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0024.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0025.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0026.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0027.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0028.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0029.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0030.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0031.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0032.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0033.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0034.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0035.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0036.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0037.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0038.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0039.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0040.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0041.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0042.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0043.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0044.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0045.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0046.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0047.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0048.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0049.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0050.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0051.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0052.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0053.JPG
`
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`

`

`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0054.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0055.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0056.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0057.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0058.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0059.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0060.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xm16\RFR0061 .JPG
`
`
`
`
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0062.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0063.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0064.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0065.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0066.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0067.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0068.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0069.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0070.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xm16\RFR0071 .JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0072.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0073.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0074.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0075.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0076.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0077.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0078.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0079.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0080.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xm16\RFR0081 .JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0082.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0083.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0084.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0085.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0086.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0087.JPG
`
`\\TICRS\EXPORT 17\IMAGEOUT17\866\064\86606416\Xm16\RFR0088.JPG
`
`\\TICRS\EXPORT 17\IMAGEOL‘T17\866\064\86606416\Xml6\RFR0089.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0054.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0055.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0056.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0057.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0058.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0059.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0060.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0061.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0062.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0063.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0064.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0065.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0066.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0067.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0068.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0069.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0070.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0071.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0072.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0073.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0074.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0075.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0076.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0077.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0078.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0079.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0080.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0081.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0082.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0083.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0084.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0085.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0086.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0087.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0088.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0089.JPG
`
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`

`

`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0090.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0091.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0092.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0093.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0094.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0095.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0096.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0097.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0098.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0099.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0100.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0101.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0102.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0103.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\866\064\86606416\xml6\RFR0104.JPG
`
`DESCRIPTION OF EVIDENCE FILE
`
`Arguments and Exhibits
`
`SIGNATURE SECTION
`
`RESPONSE SIGNATURE
`
`SIGNATORY'S NAME
`
`SIGNATORY'S POSITION
`
`SIGNATORY'S PHONE NUMBER
`
`DATE SIGNED
`
`AUTHORIZED SIGNATORY
`
`CONCURRENT APPEAL NOTICE FILED
`
`FILING INFORMATION SECTION
`
`SUBMIT DATE
`
`TEAS STAMP
`
`/NKM/
`
`Nicole K. McLaughlin
`
`Attorney of record, PA bar member
`
`215-979-1191
`
`10/06/2017
`
`YES
`
`NO
`
`Fri Oct 06 13:54:52 EDT 2017
`
`USPTO/RFR-XX.XXX.XX.XXX-2
`0171006135452423893-86606
`416-510afc2b4c7d48f2c789b
`3c1321d32c8c245828d25ee3b
`a1e831e88a63b1d713-N/A-N/
`A-20171006133904271407
`
`Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`PTO Form 1960 (Rev 10/2011)
`
`OMB No. 0651-0050 (Exp 09/20/2020)
`
`Request for Reconsideration after Final Action
`To the Commissioner for Trademarks:
`
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`

`

`Application serial no. 86606416 LISOLOG(Standard Characters, see https://tmng-al.uspto.gov/resting2/api/img/86606416/large) has been
`amended as follows:
`
`ARGUMENT(S)
`In response to the substantive refusal(s), please note the following:
`
`Please find attached argument and exhibits. 
`
`EVIDENCE
`Evidence in the nature of Arguments and Exhibits has been attached.
`Original PDF file:
`evi_1214420254-20171006133904271407_._LisologReqforRecon.pdf
`Converted PDF file(s) ( 9 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`Evidence-4
`Evidence-5
`Evidence-6
`Evidence-7
`Evidence-8
`Evidence-9
`Original PDF file:
`evi_1214420254-20171006133904271407_._lisologExhibits.pdf
`Converted PDF file(s) ( 94 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`Evidence-4
`Evidence-5
`Evidence-6
`Evidence-7
`Evidence-8
`Evidence-9
`Evidence-10
`Evidence-11
`Evidence-12
`Evidence-13
`Evidence-14
`Evidence-15
`Evidence-16
`Evidence-17
`Evidence-18
`Evidence-19
`Evidence-20
`Evidence-21
`Evidence-22
`Evidence-23
`Evidence-24
`Evidence-25
`Evidence-26
`Evidence-27
`Evidence-28
`Evidence-29
`Evidence-30
`Evidence-31
`Evidence-32
`Evidence-33
`Evidence-34
`
`

`

`Evidence—35
`Evidence—36
`Evidence—37
`Evidence—38
`Evidence—39
`Evidence—40
`Evidence—41
`Evidence—42
`Evidence—43
`Evidence—44
`Evidence—45
`Evidence—46
`Evidence—47
`Evidence—48
`Evidence—49
`Evidence—50
`Evidence—5 1
`Evidence—52
`Evidence—53
`Evidence—54
`Evidence—55
`Evidence—56
`Evidence—57
`Evidence—58
`Evidence—59
`Evidence—60
`Evidence—61
`Evidence—62
`Evidence—63
`Evidence—64
`Evidence—65
`Evidence—66
`Evidence—67
`Evidence—68
`Evidence—69
`Evidence—70
`Evidence—71
`Evidence—72
`Evidence—73
`Evidence—74
`Evidence—75
`Evidence—76
`Evidence—77
`Evidence—78
`Evidence—79
`Evidence— 80
`Evidence—81
`Evidence— 82
`Evidence—83
`Evidence— 84
`Evidence— 85
`Evidence— 86
`Evidence— 87
`Evidence—88
`Evidence— 89
`Evidence—90
`Evidence—91
`Evidence—92
`
`Evidence-35
`Evidence-36
`Evidence-37
`Evidence-38
`Evidence-39
`Evidence-40
`Evidence-41
`Evidence-42
`Evidence-43
`Evidence-44
`Evidence-45
`Evidence-46
`Evidence-47
`Evidence-48
`Evidence-49
`Evidence-50
`Evidence-51
`Evidence-52
`Evidence-53
`Evidence-54
`Evidence-55
`Evidence-56
`Evidence-57
`Evidence-58
`Evidence-59
`Evidence-60
`Evidence-61
`Evidence-62
`Evidence-63
`Evidence-64
`Evidence-65
`Evidence-66
`Evidence-67
`Evidence-68
`Evidence-69
`Evidence-70
`Evidence-71
`Evidence-72
`Evidence-73
`Evidence-74
`Evidence-75
`Evidence-76
`Evidence-77
`Evidence-78
`Evidence-79
`Evidence-80
`Evidence-81
`Evidence-82
`Evidence-83
`Evidence-84
`Evidence-85
`Evidence-86
`Evidence-87
`Evidence-88
`Evidence-89
`Evidence-90
`Evidence-91
`Evidence-92
`
`

`

`Evidence-93
`Evidence-94
`
`SIGNATURE(S)
`Request for Reconsideration Signature
`Signature: /NKM/     Date: 10/06/2017
`Signatory's Name: Nicole K. McLaughlin
`Signatory's Position: Attorney of record, PA bar member
`
`Signatory's Phone Number: 215-979-1191
`
`The signatory has confirmed that he/she is an attorney who is a member in good standing of the bar of the highest court of a U.S. state, which
`includes the District of Columbia, Puerto Rico, and other federal territories and possessions; and he/she is currently the owner's/holder's attorney
`or an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another U.S. attorney or a Canadian attorney/agent
`not currently associated with his/her company/firm previously represented the owner/holder in this matter: (1) the owner/holder has filed or is
`concurrently filing a signed revocation of or substitute power of attorney with the USPTO; (2) the USPTO has granted the request of the prior
`representative to withdraw; (3) the owner/holder has filed a power of attorney appointing him/her in this matter; or (4) the owner's/holder's
`appointed U.S. attorney or Canadian attorney/agent has filed a power of attorney appointing him/her as an associate attorney in this matter.
`
`The applicant is not filing a Notice of Appeal in conjunction with this Request for Reconsideration.
`
`Serial Number: 86606416
`Internet Transmission Date: Fri Oct 06 13:54:52 EDT 2017
`TEAS Stamp: USPTO/RFR-XX.XXX.XX.XXX-2017100613545242
`3893-86606416-510afc2b4c7d48f2c789b3c132
`1d32c8c245828d25ee3ba1e831e88a63b1d713-N
`/A-N/A-20171006133904271407
`
`        
`

`

`Request fo1· Reconsideration of Final Office Action
`
`In a Final Office Action, dated April 6, 2017 ("FOA''), the Examining Attorney
`maintained the refusal of Applicant's LISOLOG mark for "pharmaceutical preparations
`containing insulin for the treatment and prevention of diabetes; inhalers filled with insulin" based
`on a likelihood of confusion with the registered mark LIDO LOG (Registration No. 4,917,672)
`for "prescription medicines and non-prescription medicines, namely, pharmaceutical
`preparations in injectable liquid vials used as local anesthetic to relieve pain and swelling; and
`medicinal kits, comprising pharmaceutical preparations in injectable liquid vials as local
`anesthetic to relieve pain and swelling." Applicant respectfully disagrees with the Examiner's
`position and seeks reconsideration.
`
`In the FOA, the Examiner notes that"[ a ]pplicant does not dispute the similarity of the
`marks or relatedness of the goods at issue." While Applicant decided not to dispute the
`similarity of the marks or relatedness of the goods, but rather relied on its earlier filings which
`predate cited registrant's earliest date on which it can rely for purposes of priority, Applicant
`affirmatively asserts that the respective marks are not similar and the goods are unrelated, and
`therefore, no likelihood of confusion exists.
`
`I.
`
`Applicant is Penalized by the U.S. Patent and Trademark Office's ("PTO")
`Inconsistent T1·eatment
`
`Applicant understands that the Examiner has no authority to review or decide inter partes
`disputes and that the determination of likelihood of confusion is made on a case-by-case basis
`and Examiners are not bound by earlier PTO decisions in other applications. That said, it cannot
`also be the case that the PTO is allowed to penalize applicants that are unable to use their mark
`in time and are required to refile for the identical mark and the identical goods--which is the
`issue here.
`
`In its original response to Office Action, Applicant explained in detail how it has earlier
`rights in its LISOLOG mark than cited registrant's rights, yet the Examiner maintained the
`refusal to register, in part, because Applicant was unable to use its mark, which would have
`resulted in a registration, but rather Applicant filed a new application before its existing
`application became abandoned. Applicant's rights began on November 9, 2011 and are
`continuous through to the present. There was no interrnption in coverage. At all times,
`Applicant had rights in its LISOLOG mark, which were continuous and which predate that of
`cited registrant's earliest date on which it can rely. The fact that Applicant's original application
`did not result in a registration, because Applicant did not yet have use of its mark, should not be
`a basis for refusal. The PTO should recognize Applicant's uninterrnpted and continuous rights,
`and uphold its earlier decision to Allow the mark to register. Rather, the PTO is effectively
`overturning its earlier decision simply because Applicant was unable to use its mark in time and
`had to refile (before the abandonment of its original application).
`
`Applicant filed its original LISOLOG (App. No. 85468790) application on November 9,
`2011 ("the Original Application"). The Original Application was Allowed, and Applicant filed
`extension requests until it had exhausted the allowable amount of extensions, up through April
`24, 2015. On April 22, 2015, two days before the Original Application would have become
`
`

`

`abandoned (the PTO did not officially abandon until May 25, 2015), Applicant filed a new
`application for the identical mark for identical goods (App. No. 86606416 - the application that
`is the subject of this response). Cited registrant filed the application for its LIDOLOG mark on
`January 28, 2015, well after Applicant's November 9, 2011 filing date of the Original
`Application and be(ore the abandonment of Applicant's Original Application. Applicant's rights
`from its Original Application were still active, and predated cited registrant, at the time cited
`registrant filed its LIDOLOG application. Therefore, Applicant is prejudiced by the PTO 's
`actions because the Examiner in the LIDO LOG application never cited Applicant's LISOLOG
`mark as a basis for refusal, and in fact, found no mark that should bar registration and/or
`because Applicant was unable to use its mark in time and was required to refile and face re(cid:173)
`examination and the risk that the PTO fails to uphold its earlier decisions. In either situation, the
`PTO unfairly places a considerable burden on Applicant by forcing it to file an inter partes
`action, because the Examiner in the LIDO LOG application did not refuse registration based on
`Applicant's earlier application or engage in multiple rounds of written arguments with the PTO
`and potentially face never receiving a registration.
`
`This situation squarely falls within the impetus of the PTO 's Consistency Initiative, as
`this is no different (except with regard to timing) than requiring consistent treatment of two co(cid:173)
`pending applications or an application and a registration owned by the same entity. In situations
`like this, where a new application for the identical mark and identical goods has been filed before
`the abandonment of the original application (rights were uninterrupted), the new examiner
`should be required to treat the new application consistently with the original application and
`uphold the PTO 's earlier decision. Otherwise, examiners are effectively given the ability to
`become judges, and ove1tum earlier PTO decisions. The PTO is penalizing applicants that
`cannot use their mark in time and are required to refile, because they are allowing the new
`examiner to treat the new application inconsistently and essentially overturn prior PTO
`decisions, when nothing differs in the new application-the marks are identical and the goods
`are identical.
`
`Applicant respectfully requests consistent treatment and that the Examiner withdraw the
`refusal to register.
`
`II.
`
`No Likelihood of Confusion Exists
`
`Aside from the fact that Applicant has received inconsistent treatment, the refosal should
`be withdrawn as the respective marks are not confusingly similar.
`
`The R espective Marks have Different Meanings Such That No Likelihood of Confusion Exists
`
`Generally, the "sound, sight and meaning" trilogy may be used to determine whether
`marks are confosingly similar. Restatement, Tmts § 729 (1938); see also Restatement (Third) of
`Unfair Competition § 2l(a) (1995). When applying the "sound, sight and meaning" trilogy, it is
`not necessary for the Trademark Attorney to automatically find a likelihood of confusion if one
`element is found to be similar. See Jn re Lamson Oil Co., 6 U.S.P.Q.2d 1534, n.4 (T.T.A.B.
`1988).
`
`2
`
`

`

`Here, the Examiner summarily concluded that "the applied-for and registered marks are
`confusingly similar as the marks are "similar in sound"; "convey similar impressions of fanciful
`words" and are "similar in appearance." But what the Examiner misses is that- in this case-the
`prefix "LIDO" has a distinct medical meaning commonly known throughout the medical and
`pharmaceutical industries. LIDO means "lidocaine". This is evidenced by, amongst other
`sources, the U.S. government, private medical institutions, and medical publications/dictionaries.
`See attached at Exhibit A, evidence that "LIDO" means "lidocaine" from allacronyms.com, the
`Mayo Clinic and National Library of Medicine, National Institutes of Health, Department of
`Health and Human Services, which is hereby incorporated herein.
`
`Lidocaine is a drug used as a local anesthetic to prevent pain in a particular part of the
`body. See attached at Exhibit B, the definition from Cambridge English Dictionary, which is
`hereby incorporated herein. Accordingly, it would follow that the meaning/commercial
`impression of the LIDOLOG mark is related to pain relief. Not surprisingly, the LIDOLOG
`registration covers, "pharmaceutical preparations in injectable liquid vials used as local
`anesthetic to relieve pain and swelling; and medicinal kits, comprising pharmaceutical
`preparations in injectable liquid vials as local anesthetic to relieve pain and swelling." (emphasis
`added). Medical and pharmaceutical professionals know that "LIDO" means "lidocaine" and
`that a "LIDO" product is used to treat pain. Medical and pharmaceutical purchasers are highly
`educated and trained and are sophisticated purchasers that are not easily confused. Medical
`professionals will immediately understand that a product that begins with the prefix "LIDO"
`contains lidocaine and is for pain relief.
`
`Below is a photograph of the LIDOLOG specimen of use filed at the PTO during the
`prosecution of the LIDO LOG mark, which clearly identifies "lidocaine" as the first ingredient
`and also reflects that the product is "RX-ONLY".
`
`NOC 76420-760-01
`
`log
`
`t
`
`K"t Cont n
`2 Lido,aine HCI Injection, USP 2% Sinyl., Dose Amf>ule (2mLl
`1 Kenalog-40' (1 ml)
`1 Po vidone-lodine Swabstid<s l3 Swabs)
`1 Pair N'trile Powdrn- Free Sterile GkMts lSize 1 .5)
`1 Adhesive Bandage
`Non Sterile 4x4 Gauze
`
`Needles and Syringe• Not Included
`
`~by.
`
`Enovachem
`"' ANUfACTUltNG
`TQrrance. CA 90501
`
`lOi~o,t•1\n
`
`,~~;tC.·ii
`
`EXI':
`
`3
`
`

`

`In fact, the PTO register contains almost 25 active marks that begin with the prefix
`"LIDO" which are ALL for pain relief products in Class 5. Below is a sampling of these active
`applications/registrations in Class 5:
`
`Mark
`
`Reg. No./Serial No.
`
`Goods
`
`LIDOCREAM
`
`87599773 (in use)
`
`Pain relief medication; sports cream for relief of pain
`
`LIDOCAGLE
`
`79213842
`
`LIDOCAGEL
`
`792 13841
`
`Local anesthetics; topical analgesics; topical analgesic creams; alcohol for
`topical use; topical firstaid gels; inhalant anesthetics; general anesth etics;
`anesthetics for non-surgical use; anesthetics for surgical use;
`pharmaceutical preparations and substances for use in the field of
`anesthesia; anaesthetics
`
`Local anesthetics; topical analgesics; topical analgesic creams; alcohol for
`topical use; topical firstaid gels; inhalant anesthetics; general anesthetics;
`anesthetics for non-snrgical use; anesthetics for snrgical use;
`pharm aceutical preparations and substances for use in the field of
`anesthesia; anaesthetics
`
`LIDO KING
`
`87436206 (in use)
`
`Analgesic and muscle relaxant pharmaceutical preparations; transdennal
`patches for use in the treatment of pain and inflammation
`
`LIDOCIDEX
`
`87383383 (in use)
`
`LIDOCILONE
`
`87383399 (in use)
`
`Prescription medicines and non-prescription medicines, namely,
`pharmaceutical preparations in injectable liquid vials used to relieve pain
`and swelling; medicinal kits, comprising pharmaceutical preparations in
`injectable liquid vials used to relieve pain and swelling
`
`Prescription medicines and non-prescription medicines, namely,
`phannaceutical prepar·ations in injectable liquid vials used to relieve pain
`and swelling; medicinal kits, comprising phannaceutical preparntions in
`injectable liquid vials used to relieve pain and swelling
`
`LIDO-GEL
`
`87375550 (in use)
`
`Topical anesthetics containing lidocaine compound
`
`LIDOCARE
`ULTRA
`
`86972242
`
`Medicated patches for use in delivering pharmaceutical preparations for
`the treatment of pain
`
`LIDOS POT
`
`5090079
`
`Bandages impregnated with adhesive and lidocaine; dermatological
`pharmaceutical products; drng delivery agents in the form of a coating for
`bandages and patches that facilitate the delivery of a wide range of
`pharmaceuticals; phannaceutical agents for epidennis; transdermal patches
`featuring anesthetic, namely, lidocaine
`
`LIDOCARE
`
`5056088
`
`Medicated patches for use in delivering phannaceutical preparations for
`the treatment of pain
`
`LIDO MAX
`
`482662 1
`
`Transdennal patches for use in the treatment of pain
`
`LIDOFLEX
`
`4869342
`
`Bandages impregnated with adhesive and medicine; dermatological
`pharmaceutical products; drng delivery agents in the form of a coating for
`bandages and patches that facilitate the delivery of a wide range of
`pharmaceuticals; pharmaceutical agents for epidermis; transdennal patches
`featuring anesthetic, namely, lidocane
`
`LIDOPRO
`
`4778765
`
`Topical pain relief ointment
`
`4
`
`

`

`Mark
`
`Reg. No./Serial No.
`
`Goods
`
`LIDOSE
`
`4612933
`
`Drug delivery agents containing compounds that facilitate delivery of a
`wide variety of pharmaceuticals
`
`LIDOS TAT
`
`4573484
`
`Topical lidocaine cream for pocliatric pain use
`
`LIDOGESIC
`
`5027375
`
`LIDOTRANZ
`
`5027377
`
`LIDO RX
`
`451 8435
`
`Pharmaceutical preparations for topical gels and ointments for transclennal
`delivery of analgesics, anti-inflammatory agents, antineoplastic agents,
`muscle relaxants, anaesthetic agents, peptides, proteins, growth factors,
`honnones, substance p antagonists, antifungal compounds, antiviral
`compounds, antibacterial compounds, antiobesity drugs, homeopathic
`agents, antianginal compounds, hair growth stimulators or retardants,
`nutrients, and antimetabolites
`
`Pharmaceutical preparations for topical gels and ointments for transdennal
`delivery of analgesics, anti-inflammatory agents, antineoplastic agents,
`muscle relaxants, anaesthetic agents, peptides, proteins, growth factors,
`hormones, substance p antagonists, antifungal compounds, antiviral
`compounds, antibacterial compounds, antiobesity drugs, homeopathic
`agents, antianginal compounds, hair growth stimulators or retardants,
`nutrients, and antimetabolites
`
`Pharmaceutical preparations for topical gels and ointments for transdennal
`delivery of analgesics, anti-inflammatory agents, antineoplastic agents,
`muscle relaxants, anaesthetic agents, peptides, proteins, growth factors,
`honnones, substance p antagonists, antifungal compounds, antiviral
`compounds, antibacterial compounds, antiobesity drngs, homeopathic
`agents, antianginal compounds, hair growth stimulators or retardants,
`nutrients, and antimetabolites
`
`LIDOVIR
`
`422193 1
`
`Phanuaceutical preparations, namely topical antiviral analgesic
`
`LIDOPATCH
`
`4077022
`
`Transclennal patches for use in the treatment of pain
`
`LIDOCOLL
`
`4179944
`
`LIDOCORT
`
`3596398
`
`Pharmaceutical, veterinary and sanitary preparations for the treatment of
`wounds, bums and surge1y in or on the human and non-human body,
`namely, medicated and non-medicated dr·essings and sponges; and medical
`preparations in spray and gel form for the treatment of wounds and bums
`
`Medical kit containing an applicator, wipes and an anti-inflaunnatory
`anesthetic; and dermatological preparations, namely, an anti-inflammatory
`anesthetic for relief of pain,